Priming of signal transducer and activator of transcription proteins for cytokine-triggered polyubiquitylation and degradation by the A2A adenosine receptor

Molecular Pharmacology

Volumn 77, Issue 6, 2010, Pages 968-978

  Safhi, Mohammed M A ^a   Rutherford, Claire ^a   Ledent, Catherine ^b   Sands, William A ^a   Palmer, Timothy M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A2A RECEPTOR; ADENOSINE DEAMINASE; ALPHA INTERFERON; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CHLOROQUINE; CYTOKINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHENYLALANINE; PROTEASOME; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; TYROSINE; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UBIQUITINATION; VASCULAR ENDOTHELIUM; WILD TYPE;

EID: 77952401851     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.062455     Document Type: Article

References (54)

1. Anderson R, Visser SS, Ramafi G, and Theron AJ (2000) Accelerated resequestration of cytosolic calcium and suppression of the pro-inflammatory activities of human neutrophils by CGS 21680 in vitro. Br J Pharmacol 130:717-724. (Pubitemid 30389049)
2. 2A-receptor-gene-deficient mice. Biochem J 354:123-130.
3. 2C receptor systems. Mol Pharmacol 55:863-872.
4. Brierley MM and Fish EN (2002) Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry. J Interferon Cytokine Res 22:835-845.
5. Chen Y, Dai X, Haas AL, Wen R, and Wang D (2006) Proteasome-dependent down-regulation of activated Stat5A in the nucleus. Blood 108:566-574. (Pubitemid 44061357)
6. Chen ZJ (2005) Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 7:758-765.
7. Csóka B, Németh ZH, Virág L, Gergely P, Leibovich SJ, Pacher P, Sun CX, Blackburn MR, Vizi ES, Deitch EA, et al. (2007) A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood 110:2685-2695.
8. Ewan LC, Jopling HM, Jia H, Mittar S, Bagherzadeh A, Howell GJ, Walker JH, Zachary IC, and Ponnambalam S (2006) Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic 7:1270-1282. (Pubitemid 44204001)
9. Fantuzzi G and Mazzone T (2007) Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol 27:996-1003. (Pubitemid 46641984)
10. Gao C, Guo H, Mi Z, Grusby MJ, and Kuo PC (2007) Osteopontin induces ubiquitin-dependent degradation of STAT1 in RAW264.7 murine macrophages. J Immunol 178:1870-1881. (Pubitemid 46154660)
11. 278 in ligand binding and sodium modulation. Biochem Pharmacol 60:661-668.
12. Gimbrone MA Jr (1995) Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis. Am J Cardiol 75:67B-70B.
13. 2a receptor-dependent and independent mechanisms. FASEB J 14:2065-2074.
14. Haskó G and Pacher P (2008) A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 83:447-455. (Pubitemid 351966849)
15. Haskó G, Pacher P, Deitch EA, and Vizi ES (2007) Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther 113:264-275. (Pubitemid 46149045)
16. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, and Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1-20. (Pubitemid 37046923)
17. Horvath CM (2004) Weapons of STAT destruction. Interferon evasion by paramyxo-virus V protein. Eur J Biochem 271:4621-4628.
18. 2 receptors in rat brain. J Pharmacol Exp Ther 251:888-893.
19. Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, and Chen JF (2009) Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 15:406-413.
20. Kaptein A, Paillard V, and Saunders M (1996) Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction. J Biol Chem 271: 5961-5964. (Pubitemid 26095392)
21. Kim TK and Maniatis T (1996) Regulation of interferon-γ-activated STAT1 by the ubiquitin-proteasome pathway. Science 273:1717-1719.
22. 2A-adenosine receptor blunts constitutive activity: differential effect on cAMP accumulation and MAP kinase stimulation. Naunyn Schmiedebergs Arch Pharmacol 366:287-298.
23. 2A receptor gene by hypoxia in PC12 cells. A potential role in cell protection. J Biol Chem 274:20358-20365.
24. Kunisada K, Tone E, Fujio Y, Matsui H, Yamauchi-Takihara K, and Kishimoto T (1998) Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 98:346-352. (Pubitemid 28348057)
25. Lappas CM, Sullivan GW, and Linden J (2005) Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin Investig Drugs 14:797-806.
26. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, and Parmentier M (1997) Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388:674-678.
27. Levy DE and Darnell JE Jr (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3:651-662.
28. Liu YC, Penninger J, and Karin M (2005) Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol 5:941-952.
29. Lornejad-Schäfer M, Albrecht U, Poppek D, Gehrmann T, Grune T, Bode JG, Häussinger D, and Schliess F (2005) Osmotic regulation of STAT3 stability in H4IIE rat hepatoma cells. FEBS Lett 579:5791-5797.
30. Majumdar S and Aggarwal BB (2003) Adenosine suppresses activation of nuclear factor-kappaB selectively induced by tumor necrosis factor in different cell types. Oncogene 22:1206-1218.
31. McPherson JA, Barringhaus KG, Bishop GG, Sanders JM, Rieger JM, Hesselbacher SE, Gimple LW, Powers ER, Macdonald T, Sullivan G, et al. (2001) Adenosine A(2A) receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler Thromb Vasc Biol 21:791-796.
32. Nalepa G, Rolfe M, and Harper JW (2006) Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 5:596-613.
33. Nguyen DK, Montesinos MC, Williams AJ, Kelly M, and Cronstein BN (2003) Th1 cytokines regulate adenosine receptors and their downstream signaling elements in human microvascular endothelial cells. J Immunol 171:3991-3998. (Pubitemid 37238673)
34. Ohta A and Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414: 916-920. (Pubitemid 34024743)
35. Poucher SM, Keddie JR, Singh P, Stoggall SM, Caulkett PW, Jones G, and Coll MG (1995) The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist. Br J Pharmacol 115:1096-1102.
36. Ritchie SA, Ewart MA, Perry CG, Connell JM, and Salt IP (2004) The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci 107:519-532.
37. 2A adenosine receptor gene transfer. Mol Pharmacol 66:1147-1159.
38. Sands WA, Woolson HD, Milne GR, Rutherford C, and Palmer TM (2006) Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells. Mol Cell Biol 26:6333-6346. (Pubitemid 44277875)
39. Schäfer K, Halle M, Goeschen C, Dellas C, Pynn M, Loskutoff DJ, and Konstantinides S (2004) Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 24:112-117.
40. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, and Drexler H (2000) Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101:1372-1378.
41. 2A-adenosine receptor in primary human endothelial cells. J Biol Chem 272:5792-5799.
42. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, and Thiel M (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22:657-682. (Pubitemid 38680437)
43. 2A receptor agonists. Br J Pharmacol 132:1017-1026.
44. Tanaka T, Soriano MA, and Grusby MJ (2005) SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity 22:729-736. (Pubitemid 40814503)
45. Tilg H and Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772-783. (Pubitemid 44453463)
46. van Weert AW, Dunn KW, Gueze HJ, Maxfield FR, and Stoorvogel W (1995) Transport from late endosomes to lysosomes, but not sorting of integral membrane proteins in endosomes, depends on the vacuolar proton pump. J Cell Biol 130:821-834.
47. Vischer HF, Leurs R, and Smit MJ (2006) HCMV-encoded G-protein-coupled receptors as constitutively active modulators of cellular signaling networks. Trends Pharmacol Sci 27:56-63.
48. von der Thüsen JH, Kuiper J, van Berkel TJ, and Biessen EA (2003) Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 55:133-166. (Pubitemid 36268401)
49. Wang D, Moriggl R, Stravopodis D, Carpino N, Marine JC, Teglund S, Feng J, and Ihle JN (2000) A small amphipathic alpha-helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5. EMBO J 19:392-399. (Pubitemid 30072609)
50. Watson IR and Irwin MS (2006) Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia 8:655-666.
51. Williams L, Bradley L, Smith A, and Foxwell B (2004) Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 172:567-576.
52. Xu Y, Ravid K, and Smith BD (2008) Major histocompatibility class II transactivator expression in smooth muscle cells from A2b adenosine receptor knock-out mice: cross-talk between the adenosine and interferon-gamma signaling. J Biol Chem 283:14213-14220.
53. Yarwood SJ, Borland G, Sands WA, and Palmer TM (2008) Identification of CCAAT/ enhancer-binding proteins as exchange protein activated by cAMP-activated transcription factors that mediate the induction of the SOCS-3 gene. J Biol Chem 283:6843-6853.
54. Zernecke A, Bidzhekov K, Ozüyaman B, Fraemohs L, Liehn EA, Lüscher-Firzlaff JM, Lüscher B, Schrader J, and Weber C (2006) CD73/ecto-5′-nucleotidase protects against vascular inflammation and neointima formation. Circulation 113: 2120-2127. (Pubitemid 43755163)